Drug intelligence / Profile preview

AB-CD01

Development stage: Preclinical
Lead developer: University of Leicester
Modality: Live Biotherapeutic Products → Microbiome Therapeutics

Overview

**AB-CD01** is a preclinical, seven-bacteriophage cocktail developed for **Clostridioides difficile infection**. The product was licensed from the University of Leicester by AmpliPhi Biosciences as AmpliPhage-004 and was designed to use lytic bacteriophages to selectively infect and kill susceptible *C. difficile* bacteria. Public AmpliPhi materials described efficacy in an animal model and plans for manufacturing, but no clinical development of AB-CD01 was identified. ([sec.gov](https://www.sec.gov/Archives/edgar/data/921114/000114420416074960/v428747_ex99-1.htm))

Beyond the preview

Go deeper on AB-CD01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-CD01.

Explore the full profile